Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.87, while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| BOTZ | XBI | |
|---|---|---|
52-Week High | $41.63 | $164.28 |
52-Week Low | $31.99 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.92, up 1.34% with a bullish technical signal supported by moving averages. The robotics and AI ETF shows strong momentum with key resistance at $38. Recent articles highlight BOTZ as the largest pure-play robotics fund, positioned to benefit from the shift from digital to physical AI applications. The fund offers exposure to global robotics leaders with a lower expense ratio than peers.
Outlook remains positive as robotics adoption accelerates globally, though overbought RSI signals near-term caution. Investment opportunity lies in AI's expansion into physical automation, while risks include sector concentration and valuation pressures in tech. The fund's global diversification provides exposure to non-US AI innovation.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
